Despite resilient demand, healthcare has taken a hit along with the rest of the market. This Big Pharma could boost profits ...

Big Pharma and biotech startups alike are counting on AI to speed the process of drug discovery and make their operations ...

Nearly a year after winning an accelerated approval for its DLL3-targeting small cell lung cancer (SCLC) therapy Imdelltra, ...

The bispecific antibody helped people with small cell lung cancer live longer, Amgen said. Elsewhere, J&J shared new autoimmune drug data and Alzheon reported an Alzheimer’s drug failure.

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Amgen (AMGN) to $330 from $328 and keeps an Equal Weight rating on the ...

With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Dexcom (DXCM – Research Report) and Amgen (AMGN – Research ...

The threat of tariffs has put the pharma industry through the wringer this week. On Wednesday, a week after instituting widespread tariffs and a day after promising that “major” tariffs were headed ...

The FDA approved Amgen ’s anti-CD19 therapy Uplizna Thursday for use in patients with IgG4-related disease. Uplizna is the ...

Analysts believe the key question is whether India can be exempted from the pharma tariffs, given the better relationship ...